Cite
918 Treatment-related adverse event (TRAE)-related discontinuation rate of immunotherapy alone (IO-only) compared to immunotherapy combined with chemotherapy (chemo-IO): a meta-analysis
MLA
Seunghwan Shin, et al. “918 Treatment-Related Adverse Event (TRAE)-Related Discontinuation Rate of Immunotherapy Alone (IO-Only) Compared to Immunotherapy Combined with Chemotherapy (Chemo-IO): A Meta-Analysis.” Regular and Young Investigator Award Abstracts, Nov. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........782545fd436e67c08238aae3ddb502e1&authtype=sso&custid=ns315887.
APA
Seunghwan Shin, Sumin Lee, Huijeong Kim, Chiyoon Oum, SooIck Cho, Yoojoo Lim, Ken Nesmith, & Chan-Young Ock. (2022). 918 Treatment-related adverse event (TRAE)-related discontinuation rate of immunotherapy alone (IO-only) compared to immunotherapy combined with chemotherapy (chemo-IO): a meta-analysis. Regular and Young Investigator Award Abstracts.
Chicago
Seunghwan Shin, Sumin Lee, Huijeong Kim, Chiyoon Oum, SooIck Cho, Yoojoo Lim, Ken Nesmith, and Chan-Young Ock. 2022. “918 Treatment-Related Adverse Event (TRAE)-Related Discontinuation Rate of Immunotherapy Alone (IO-Only) Compared to Immunotherapy Combined with Chemotherapy (Chemo-IO): A Meta-Analysis.” Regular and Young Investigator Award Abstracts, November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........782545fd436e67c08238aae3ddb502e1&authtype=sso&custid=ns315887.